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Medullary thyroid carcinoma currently accounts for 5–8% of all thyroid cancers. The clinical course of this disease varies
from extremely indolent tumors that can go unchanged for years to an extremely aggressive variant that is associated
with a high mortality rate. As many as 75% of all medullary thyroid carcinomas are sporadic, with an average age at
presentation reported as 60 years, and the remaining 25% are hereditary with an earlier age of presentation, ranging
from 20 to 40 years. Germline RET proto-oncogene mutations are the genetic causes of multiple endocrine neoplasia
type2 and astronggenotype-phenotype correlationexists,particularlybetweena specificRET codon mutationand the
(a) age-related onset and (b) thyroid tumor progression, from C-cell hyperplasia to medullary thyroid carcinoma and,
ultimately, to nodal metastases. RET mutations predispose an individual to the development of medullary thyroid
carcinomas and can also influence the individual response to RET protein receptor-targeted therapies. RET codon 609-
point mutations are rare genetic events belonging to the intermediate risk category for the onset of medullary thyroid
carcinoma. A large genealogy resulting in a less aggressive form of medullary thyroid carcinoma is associated with the
high penetrance of pheochromocytoma and has been reported in the literature. In this short review article, we
comment on our previous report of a large multiple endocrine neoplasia type 2A kindred with the same Cys609Ser
germline RET mutation in which, conversely, the syndrome was characterized by a slightly aggressive, highly penetrant
form of medullary thyroid carcinoma that was associated with low penetrance of pheochromocytoma and primary
hyperparathyroidism.
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INTRODUCTION
Medullary thyroid carcinoma (MTC) currently accounts for
5–8% of all thyroid cancers. It arises from the parafollicular C-
cells originating from the neural crest that are incorporated
into the thyroid during fetal development. The clinical course
of MTC varies from extremely indolent tumors that can go
unchanged for years to extremely aggressive variants that are
associated with a high mortality rate.
The relationship between proto-oncogene RET mutations
and MTC is one of the best examples of translational
medicine. RET mutations predispose an individual to the
development of parafollicular C-cell hyperplasia and, subse-
quently, to the onset of MTC. Most of the sporadic MTC cases
harbor a somatic RET mutation that can be correlated with
disease aggressiveness. Up to 20–30% of the subjects with an
apparently sporadic MTC have a germline mutation (1).
Hereditary MTC can occur as three major subtypes:
multiple endocrine neoplasia type 2A (MEN2A), multiple
endocrine neoplasia type 2B (MEN2B), or familial MCT
(FMTC). When the RET mutation presents at the germline
level, the disease, either FMTC or MEN2, is transmitted as an
autosomal-dominant trait with complete penetrance. In
MEN2A, in addition to MTC (100% of cases), patients
develop pheochromocytoma (PHEO) and primary hyperpar-
athyroidism (HPT) in approximately 50% and 20% of cases,
respectively. The MEN2B phenotype is characterized by the
presence of mucosal neuromas and marfanoid habitus as
well as MTC (100% of cases) and PHEO (50% of cases) (1).
In this syndrome, the phenotype-genotype correlation is
strong. Thus, different codon mutations along the RET
oncogene predispose individuals to different ages of onset
and disease aggressiveness. Also, the specific RET codon
mutation can influence decisions about surgical prophylac-
tic thyroid intervention.
Complete penetrance, autosomal-dominant transmission,
strong phenotype-genotype correlation, and a relatively sim-
ple genomic structure are the key points of the success of RET,
as an example, in translational medicine. For these reasons, the
detection of germline RET mutations is now broadly accepted
for the clinical evaluation of subjects with MTC.
The RET gene is localized on chromosome 10, band
10q11.2; it is comprised of 21 exons and encodes for the RET
transmembrane receptor with intrinsic tyrosine kinase (TK)
activity and is stimulated by interaction with different
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33growth factors belonging to the glial-derived neurotrophic
factor family. In animal models, RET is essential for the
development of the sympathetic and parasympathetic
enteric nervous systems and the kidneys.
In 98% of MEN2A families, germline mutations affect the
cysteine-rich extracellular domain by converting a cysteine
into another amino acid, and by determining RET sponta-
neous dimerization and activation. These mutations are
located in codon 634 (exon 11) or codons 609, 611, 618, and
620 (exon 10). The most common mutation, accounting for
80% of MEN2A families, affects codon 634, and in this
codon a particular point mutation, when a cysteine is
substituted for an arginine, accounts for 50% of all MEN2A
cases. Approximately half of FMTC kindred are due to
germline mutations in exon 10 (codon 618 and 620), but
some FMTC families are caused by mutations in exon 11
(codons 630, 631 or 634). Interestingly, the cysteine-arginine
substitution in the RET 634 codon has never been found in
FMTC families. In an increasing number of FMTC cases,
germline mutations have been reported in exons 13 (codons
768, 790 and 791), 14 (codon 804 and 844), and 15 (codon
891), which are located in the TK domain, thereby
interfering with intracellular ATP binding. In approximately
95% of patients with MEN2B, a single mutation that
converts methionine to threonine at codon 918 (exon 16)
has been identified (1). This mutation causes alterations in
the substrate recognition pocket of the TK catalytic core.
Other rare intracellular mutations that are associated with
MEN2B involve codon 882 (exon 15).
There is a close relationship between genotype and
phenotype. Thus, more aggressive phenotypes have been
noticed in cases carrying mutations in the extracellular
portion of RET rather than the intracellular portion.
Furthermore, the average age at diagnosis for MEN2
patients with C-cell hyperplasia and RET extracellular
domain mutations is 8.3 years, whereas the average age at
diagnosis is of 11.2 years in patients with RET intracellular
domain mutations. In patients with node-negative MTC, the
average age at diagnosis is 10.2 years for patients with the
associated extracellular domain mutations and 16.6 years
for patients harboring intracellular domain mutations (2).
The strong genotype-phenotype correlation and the age-
related progression of MTC based on the type of RET
mutation has enabled researchers to identify different classes
of risk regarding MTC penetrance and aggressiveness. Thus,
a ‘‘codon-directed’’ appropriate timing for surgery in RET
mutation carriers has been defined. Patients with level 3
mutations (codons 883, 918 and 922) are at the highest risk of
developing aggressive MTC, while patients with level 2
mutations (codons 611, 618, 620 and 634) are at intermediate
risk and patients with level 1 mutations (codons 768, 790, 791,
804 and 891) are at the lowest risk (3).
The RET codon 609 mutation
RET mutations in codon 609 are extremely rare genetic
events in patients with MEN2A (,1% of all reported cases)
and were initially considered as level 1 mutations (4).
However, after the publication of a family pedigree carrying
the RET 609 cysteine-to-glycine substitution, in which a RET
mutation carrier was diagnosed with MTC at 5 years of age
(5), some authors shifted the RET codon 609 mutations from
risk level 1 to risk level 2 (6).
One way to overcome the relatively poor information
available regarding the genotype-phenotype correlation in
patients with the RET codon 609 mutation is to take into
account descriptions of large, affected families and registry
studies with sufficiently large numbers of individuals with
the RET 609 codon mutation.
Several large families with RET codon 609 mutations have
been reported in the literature. In the family reported by
Kinlaw et al. (7), carriers of the RET codon 609 cysteine-to-
serine substitution were characterized by the low pene-
trance of MTC and the high penetrance of PHEO. Calva
et al. (8) described 16 affected patients belonging to a 38-
member genealogy with a RET Cys609Tyr mutation. The
phenotype of these subjects was characterized by MTC in
nine out of 16 affected cases, lymph node metastasis in six
out of nine cases, parathyroid adenoma in one out of 16
cases; however, PHEO was not found in this family.
We have also described a 5-generation, 48-member family
with MEN2A syndrome that also harbored the RET
Cys609Tyr mutation (9). Furthermore, a large registry study
of individuals carrying RET exon 10 mutations, which also
includes this family, was published by Frank-Raue et al. (10).
Description of the Italian RET C609S pedigree
The proband was a 36-year-old man. He had a 12-mm
hypoechogenic, highly vascularized thyroid node of inde-
terminate cytology and a serum calcitonin (CT) level of
76 pg/ml. His family history was remarkable in terms of
MTC and PHEO, but a previous genetic test on one of his
affected relatives had failed to identify known any RET
mutations.
Urinary metanephrines and adrenal computed tomogra-
phy revealed no biochemical or radiological signs of PHEO;
serum PTH, calcium and phosphorus levels were also
within the normal ranges. The patient underwent a total
thyroidectomy and central neck dissection, and the histolo-
gical diagnosis was MTC without lymph node involvement
(T1mN0Mx).
His genealogy included five already diagnosed cases of
MTC. Two subjects had isolated MTC, three had lymph-
node-positive MTC, and one had liver metastasis. Two out
of five patients had PHEO (which was the first clinical sign
of MEN2A syndrome in one case).
RET analysis, which was reconsidered in the proband,
revealed a codon 609 mutation (TGC609TCC) that lead to a
cysteine-to-serine substitution, Cys609Ser. This mutation
was also confirmed in the members of his family already
known to be affected. Another 24 family members under-
went genetic testing for this RET mutation, revealing nine
carriers (Figure 1). Two at-risk individuals refused genetic
investigations.
Phenotypic characterization of the gene mutation
carriers
In short, clinical investigation revealed that none of the
patientshada palpablethyroidnode. None ofthenodeswere
larger than 10 mm in diameter, presented with a suspected
echographic pattern on ultrasound or had hypertension; one
patient hadtwoepisodes ofnephrolithiasisasthe firstclinical
sign of the syndrome. Serum CT measurements revealed that
the older subjects, one of whom was an 86-year-old woman,
had the highest basal CT levels, while those of the younger
subjects were low or unresponsive to pentagastrin. None of
the patients had biochemical or radiological evidence of
PHEO. All patients who underwent thyroid surgery demon-
strated isolated MTC and/or C-cell hyperplasia.
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carriers and recommendations
The 1999 consensus statement on MEN recommended
that codon 609 RET mutations should be considered as risk
level 1, for which there are no unequivocal clinical
management guidelines. Some clinicians recommend a
prophylactic total thyroidectomy by the age of 5 years,
others by the age of 10 years, whereas others advocate
surgery as soon as routine pentagastrin-stimulated test
findings become abnormal (3).
Indeed, 609 RET mutations are quite rare genetic events at
the onset of MEN2A and few affected families have been
described in the literature (7,9,10,11,12). One family was
comprised a 5-year-old boy who harbored a Cys609Gly
substitution that is associated with an invasive MTC at final
histology and warranting the inclusion of such mutations in
the intermediate risk category (5,6). On the other hand, in
vitro data obtained from transfected NIH3T3 cells seem to
suggest that 609 mutations have a smaller capacity for
neoplastic transformation than other level 2 RET mutations
(13). Only one large family carrying a Cys609Ser mutation
was reported by Kinlaw et al. and, regarding its clinical
aspects, this genealogy revealed an unusual phenotype
characterized by a scarcely penetrant, non-aggressive MTC
(20%) and a tendency for cases to present with PHEO rather
than MTC (7). We described a kindred with the same RET
mutation. Based on the large number of affected subjects
with this specific mutation in this family who had under-
gone total thyroidectomy, we agree that the Cys609Ser
mutation carries a level 1 risk: we saw no MTC develop
before the age of 17 years, no lymph node metastases up to
30 years of age and no distant metastases up to 60 years of
age. There was also an 86-year-old mutation carrier who did
not undergo surgery. Moreover, we saw no anticipation
effect, which is by no means rare in MEN2A kindreds
carrying level 1 mutations, leading to MTC onset at an
earlier age in each successive generation (14).
MTC was highly penetrant in our family (75% of cases)
and was the first sign of disease in all but two cases (one
presented with PHEO and another presented with the
clinical consequences of primary HPT); the penetrance of
PHEO and primary HPT was low. Furthermore, the paper
by Frank-Raue et al. (10) was a very large registry study on
RET exon 10 mutations. In this study, the 45 carriers of RET
codon 609 mutations, each with different cysteine substitu-
tions (including 15 individuals belonging to the Italian
C609S pedigree), demonstrated a less aggressive MTC but a
50% penetrance of PHEO (10).
In conclusion, the results obtained in this study of large
genealogies may be very helpful for establishing a better
genotype-phenotype correlation. In particular, the results
we obtained by analyzing this very large MEN2 kindred
suggest that carriers of the Cys609Ser RET mutation can be
considered as risk level 1, for which non-aggressive clinical
management may be indicated. Thus, as also reported by
Frank-Raue et al. (10), in these cases, prophylactic total
thyroidectomy may be postponed until after 5 years of age if
careful yearly monitoring of stimulated calcitonin levels is
implemented.
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